SCHEMBL18148043

SCHEMBL18148043

COc1c(C=CC(=O)NCc2ccco2)c(NS(=O)(=O)c2cccc3occc23)cc2c1OCO2

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNKSR1 Q969H4 8/20 0.57
ALDH1A1 P00352 6/20 0.46
HPGD P15428 3/20 0.46
KDM4E B2RXH2 3/20 0.46
POLB P06746 3/20 0.46
RAB9A P51151 1/20 0.42
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
GAA P10253 1/20 0.40
MAPT P10636 3/20 0.39
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KMT2A Q03164 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
APEX1 P27695 1/20 0.38
RECQL P46063 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18148040 1.00 CNKSR1 (0.57) CNKSR1ALDH1A1HPGDKDM4EPOLB
SCHEMBL18148085 0.89 CNKSR1 (0.53) CNKSR1ALDH1A1HPGDKDM4EPOLB
SCHEMBL18148089 0.89 CNKSR1 (0.53) CNKSR1ALDH1A1HPGDKDM4EPOLB
SCHEMBL18148195 0.88 CNKSR1 (0.56) CNKSR1ALDH1A1HPGDKDM4EPOLB
SCHEMBL18148198 0.88 CNKSR1 (0.56) CNKSR1ALDH1A1HPGDKDM4EPOLB
SCHEMBL20798603 0.84 CNKSR1 (0.54) CNKSR1ALDH1A1KDM4EPOLBMAPT
SCHEMBL18163745 0.84 CNKSR1 (0.79) CNKSR1ALDH1A1HPGDKDM4EPOLB
SCHEMBL18148211 0.74 ALDH1A1 (0.42) CNKSR1ALDH1A1HPGDKDM4EPOLB
SCHEMBL18148067 0.74 POLB (0.44) CNKSR1ALDH1A1HPGDKDM4EPOLB
SCHEMBL18163743 0.73 CNKSR1 (1.00) CNKSR1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10227356-B2 Compounds, compositions and methods for inhibiting CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2019-03-12 US disclosed
US-20160304533-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2016-10-20 US disclosed
US-20160304533-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2016-10-20 US disclosed
US-20160304533-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2016-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10227356-B2 Compounds, compositions and methods for inhibiting CNKSR1 CNKSR1, CAMKK1, CNR1 CNKSR1 1/4885ALDH1A1 4731/4885HPGD 3849/4885
US-20160304533-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 CNKSR1, CAMKK1, CNR1 CNKSR1 1/4885ALDH1A1 4731/4885HPGD 3849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.